IMVT Insider Trading
Insider Ownership Percentage: 5.90%
Insider Buying (Last 12 Months): $336,900,200.00
Insider Selling (Last 12 Months): $6,819,306.60
Immunovant Share Price & Price History
Current Price: $14.68
Price Change: ▼ Price Decrease of -0.11 (-0.74%)
As of 04/11/2025 05:00 PM ET
Immunovant Insider Trading History
Immunovant Institutional Trading History
Data available starting January 2016
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More on Immunovant
Today's Range
Now: $14.68
52 Week Range
Now: $14.68
Volume
1,862,077 shs
Average Volume
1,190,097 shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.81
Who are the company insiders with the largest holdings of Immunovant?
Immunovant's top insider shareholders include:
- Sciences Ltd Roivant (Director)
- Peter Salzmann (CEO)
- Julia G Butchko (Insider)
- Eva Renee Barnett (CFO)
- William L Macias (Insider)
- Mark S Levine (Insider)
- Jay S Stout (CTO)
- Michael Geffner (Insider)
- Andrew J Fromkin (Director)
Learn More about top insider investors at Immunovant.
Who are the major institutional investors of Immunovant?
Which institutional investors are buying Immunovant stock?
Within the previous quarter, IMVT stock was bought by institutional investors including:
- GAMMA Investing LLC
- Rhumbline Advisers